Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04471974	Phase II	Enzalutamide + Pembrolizumab + ZEN-3694	ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer	Recruiting	USA	0
NCT02546661	Phase I	Danvatirsen + Durvalumab Durvalumab + Selumetinib AZD4547 Durvalumab + Olaparib Durvalumab AZD4547 + Durvalumab Durvalumab + Vistusertib Adavosertib + Durvalumab	Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)	Active, not recruiting	USA \| GBR \| FRA \| ESP \| CAN	0
NCT06126276	Phase II	Neratinib Neratinib + Palbociclib	Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	Recruiting	USA	0
NCT04116541	Phase II	Alectinib Cabozantinib Ribociclib + Siremadlin	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT04926181	Phase II	Apalutamide + Cetrelimab	Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer	Active, not recruiting	USA	0
NCT05843253	Phase II	Everolimus + Ribociclib	Study of Ribociclib and Everolimus in HGG and DIPG	Not yet recruiting	USA \| NLD \| GBR \| DEU \| CAN \| AUS	0
NCT04432454	Phase II	Abemaciclib + Lasofoxifene	Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII)	Active, not recruiting	USA	0
NCT05696626	Phase III	Abemaciclib + Fulvestrant Abemaciclib + Lasofoxifene	Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	9
NCT05933395	Phase II	Abemaciclib + Fulvestrant Fulvestrant + Neratinib Alpelisib + Fulvestrant Everolimus + Fulvestrant	Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (GERTRUDE)	Recruiting	USA	0
NCT05940493	Phase II	Abemaciclib	Abemaciclib in Newly Diagnosed Meningioma Patients	Not yet recruiting	USA	0
NCT04412629	Phase II	Cabozantinib	Cabozantinib in High Grade Neuroendocrine Neoplasms	Recruiting	USA	0
NCT03567642	Phase I	Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib	A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers	Active, not recruiting	USA	0
NCT04388852	Phase I	DS-3201b + Ipilimumab	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Recruiting	USA	0
NCT04592237	Phase II	Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	Recruiting	USA	0
NCT04129151	Phase II	Ganitumab + Palbociclib	Palbociclib + Ganitumab In Ewing Sarcoma	Completed	USA	0
NCT03834740	Phase I	Everolimus + Ribociclib	A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Completed	USA	0
NCT05673811	Phase II	Gemcitabine + Nab-paclitaxel + VCN-01 Gemcitabine + Nab-paclitaxel	Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer (VIRAGE)	Recruiting	USA \| ESP	0
NCT03434262	Phase I	Ribociclib + Trametinib Filgrastim + Gemcitabine + Ribociclib Ribociclib + Sonidegib	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors	Active, not recruiting	USA	0
NCT05986071	Phase Ib/II	Fulvestrant + M1774	I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX)	Not yet recruiting	FRA	0
NCT04391595	Phase I	Abemaciclib + LY3214996	LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients	Recruiting	USA	0
NCT02334527	Phase II	Palbociclib	Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy	Terminated	USA	0
NCT03535506	Phase II	Palbociclib	Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery (WI223281)	Terminated	USA	0
NCT02599363	Phase I	Paclitaxel + Ribociclib	A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer	Completed	USA	0
NCT03526250	Phase II	Palbociclib	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT03009201	Phase I	Doxorubicin + Ribociclib	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery	Completed	USA	0
NCT02255461	Phase I	Palbociclib	Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors	Terminated	USA	0
NCT03114527	Phase II	Everolimus + Ribociclib	Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)	Active, not recruiting	USA	0
NCT03110744	Phase II	Palbociclib	CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601)	Completed	DEU	0
NCT03781960	Phase II	Abemaciclib + Nivolumab	Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma	Terminated	USA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT01522989	Phase I	Fluorouracil + Oxaliplatin + Palbociclib	PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies	Unknown status	USA	0
NCT02933736	Phase 0	Ribociclib	Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients	Active, not recruiting	USA	0
NCT03130439	Phase II	Abemaciclib	Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer	Terminated	USA	0
NCT01356628	Phase II	Palbociclib	A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer	Active, not recruiting	USA	0
NCT02524119	Phase II	Ribociclib	LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001)	Terminated	USA	0
NCT04316169	Phase I	Abemaciclib + Anastrozole + Hydroxychloroquine Abemaciclib + Fulvestrant + Hydroxychloroquine Abemaciclib + Hydroxychloroquine Abemaciclib + Hydroxychloroquine + Letrozole	Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer	Withdrawn	USA	0
NCT03355794	Phase I	Everolimus + Ribociclib	A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)	Completed	USA	0
NCT04040205	Phase II	Abemaciclib	Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration	Recruiting	USA	0
NCT02030483	Phase I	Palbociclib Dexamethasone Lenalidomide	Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma	Terminated	USA	0
NCT02555189	Phase Ib/II	Ribociclib Enzalutamide	Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression	Completed	USA	0
NCT04555837	Phase Ib/II	Alisertib + Pembrolizumab	Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer	Active, not recruiting	USA	0
NCT04074785	Phase I	Abemaciclib + Bevacizumab	Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6	Active, not recruiting	USA	0
NCT05655598	Phase I	Palbociclib + Pimitespib	TAS-116 Plus Palbociclib in Breast and Rb-null Cancer	Recruiting	USA	0
NCT04010357	Phase II	Abemaciclib	Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC	Recruiting	USA	0
NCT02981940	Phase II	Abemaciclib	A Study of Abemaciclib in Recurrent Glioblastoma	Active, not recruiting	USA	0
NCT04118036	Phase II	Abemaciclib + Pembrolizumab	Abemaciclib + Pembrolizumab In Glioblastoma	Withdrawn	USA	0
NCT03220646	Phase II	Abemaciclib	Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors	Active, not recruiting	USA	0
NCT03356223	Phase II	Abemaciclib	Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL)	Completed	FRA	0
NCT05691465	Phase II	lutetium Lu 177 dotatate	Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells	Recruiting	USA	0
NCT03360721	Phase II	Abiraterone + Apalutamide + Prednisone	Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer	Active, not recruiting	USA	0
NCT01976169	Phase I	Ado-trastuzumab emtansine + Palbociclib	Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)	Completed	USA	0
NCT05712941	Phase III	G1T38 + Letrozole Letrozole	Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer	Withdrawn		0
NCT02873975	Phase II	Prexasertib	A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	Completed	USA	0
NCT02059213	Phase II	Goserelin Palbociclib Bicalutamide Leuprolide	A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer	Completed	USA	0
NCT05384119	Phase Ib/II	C188-9 + Palbociclib C188-9 + Fulvestrant C188-9 + Ribociclib Fulvestrant	Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer	Active, not recruiting	USA	0
NCT04469764	Phase II	Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib	Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer	Recruiting	USA	0

Gene Detail

Contact

Filtering

Sorting